NCT00093626View on ClinicalTrials.gov

Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

September 30, 2007

Study Completion Date

January 31, 2011

Conditions
Primary Peritoneal CarcinomaRecurrent Ovarian Carcinoma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Sorafenib Tosylate

Given orally

Trial Locations (1)

19103

Gynecologic Oncology Group, Philadelphia

All Listed Sponsors
collaborator

Gynecologic Oncology Group

NETWORK

lead

National Cancer Institute (NCI)

NIH

NCT00093626 - Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer | Biotech Hunter | Biotech Hunter